Marbofloxacin — products, DINs, and Canadian availability

This page lists Health Canada–registered pharmaceutical products whose active ingredient list includes Marbofloxacin. We track 6 distinct Drug Identification Numbers (DINs) for this molecule, of which 6 are currently in marketed status. Across those registrations there are 2 manufacturers or marketing authorization holders, 3 dosage forms, and 6 distinct strength presentations.

Procurement teams normally arrive here for one of three reasons: a specific brand is unavailable and an equivalent registration is needed; a clinical protocol requires a comparator containing Marbofloxacin in a defined strength; or a pharmacy needs to know which manufacturers still hold an active Canadian registration before committing to a substitution. The table below answers the first question directly. For the second and third, Nexara Health can confirm live availability, remaining shelf life, and landed cost from Canadian stock or from any of more than 40 regulated international source markets.

Registration status is not the same as availability. A product can hold marketed status in the Drug Product Database and still be on allocation, discontinued by the holder, or unavailable in the pack size a hospital needs. Where a Marbofloxacin product is in shortage, our Canadian drug shortage tracker carries the reported status, the reason where the manufacturer has published one, and the marketed alternatives sharing the same active ingredient.

Dosage forms and strengths recorded for Marbofloxacin

Dosage forms: Suspension, Solution, Tablet. Strengths: 3 MG, 160 MG, 200 MG, 100 MG, 50 MG, 25 MG.

Manufacturers and marketing authorization holders

VETOQUINOL N A INC, ZOETIS CANADA INC.

Registered products containing Marbofloxacin

Sourcing Marbofloxacin through a licensed wholesaler

Nexara Health imports and distributes under Health Canada Drug Establishment Licence #3-002896. For Marbofloxacin we can quote Canadian-marketed presentations, equivalent registrations from the EU, UK, US, Switzerland, Australia, and Japan where the Canadian presentation is unavailable, and comparator-grade supply with Certificate of Analysis, batch and expiry records, and full chain of custody for clinical trial use. Cold-chain presentations ship under GDP conditions with continuous temperature monitoring.

Related pages

• Browse all active ingredients
• Canadian drug shortage tracker
• Alternatives to Marbofloxacin
• Comparator sourcing for clinical trials